Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Abstract Background Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and pat...

Full description

Bibliographic Details
Main Authors: Gizem Oner, Semen Önder, Hüseyin Karatay, Naziye Ak, Mustafa Tükenmez, Mahmut Müslümanoğlu, Abdullah İğci, Ahmet Dincçağ, Vahit Özmen, Adnan Aydiner, Ekrem Yavuz, Neslihan Cabioğlu
Format: Article
Language:English
Published: BMC 2021-09-01
Series:World Journal of Surgical Oncology
Subjects:
Triple-negative breast cancer
PD-L1 expression
Prognosis
Neoadjuvant chemotherapy response
Online Access:https://doi.org/10.1186/s12957-021-02361-9

Internet

https://doi.org/10.1186/s12957-021-02361-9

Similar Items